Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
The combination treatment increased tumor antigen–reactive CD8 + T cells and M1-like proinflammatory macrophages and decreased immunosuppressive and tumor-promoting populations, including activated CCR8 + regulatory T cells, LRRC15 + cancer-associated fibroblasts (CAFs), RGS5 + pericytes, and APLN + tip cells.
Appeared: Friday, November 6. Science Translational Medicine. Peer-reviewed journal.